Tag Archives: Ariad Pharmaceuticals

Business, Finance, Occupation & Industry

Concerns Swirl Over Critical Drug Launch

Leave a comment

By David Williamson, The Motley Fool

Filed under:

In the following video, Motley Fool health-care analyst David Williamson discusses Ariad Pharmaceuticals , as the company’s stock reverses direction today, up 3% following yesterday’s tumble. He notes the results of a boutique institutional research survey that found Ariad’s new drug Iclusig to have toxicity concerns, and even more negative information coming from the FDA, citing blood clots and liver toxicity. David tells investors what the potential for this drug is, and whether it has a shot at success on the market despite these safety concerns.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool‘s free report, “3 Stocks That Will Help You Retire Rich,” names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Concerns Swirl Over Critical Drug Launch originally appeared on Fool.com.


David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';

var s = document.getElementsByTagName('script')[0];
s.parentNode.insertBefore(ga, s);
})();

<p style="clear: both;padding: 8px 0 0 0;height: 2px;font-size: 1px;border: 0;margin: 0;padding: …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Is IBM's Watson Really a Big Deal?

Leave a comment

By Max Macaluso, Ph.D., Brenton Flynn, and David Williamson, The Motley Fool

Filed under:

From cutting edge science to the impact of Obamacare, from clinical trial results to FDA decisions, and from Bieber fever to hay fever, The Motley Fool’s health-care team sits down each week to discuss the most fascinating developments across the health-care industry, and their implications for long-term investors. In this week’s edition, the team talks about an exciting drug approval, how computers can help scientists develop new drugs, and stocks that have both soared and crashed. The analysts close with a discussion of companies they will be closely following in the coming weeks.

In the segment below, health-care analyst Max Macaluso discusses the impact that IBM‘s Watson supercomputer could have on health care, and highlights one important area of medicine where computers have helped biotechs like Ariad Pharmaceuticals .

What macro trend was Warren Buffett referring to when he said,This is the tapeworm that’s eating at American competitiveness?” Find out in our free report, What’s Really Eating At America’s Competitiveness? You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

The relevant video segment can be found between 6:13 and 8:06.

The article Is IBM’s Watson Really a Big Deal? originally appeared on Fool.com.


Brenton Flynn has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool owns shares of International Business Machines. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

5 Stocks That Fell Every Day Last Week

Leave a comment

By Rick Aristotle Munarriz, The Motley Fool

Filed under:

Some stocks take a pounding, but there’s usually what they call a dead-cat bounce. Even if a stock‘s inevitable path is to head lower, there’s usually a respite in the downticks.

It doesn’t always pan out that way.

Last week was rather uneventful for the market. The Dow 30, Nasdaq, and S&P 500 all closed lower, but none of the market gauges shed more than 0.2% of their value.

Some stocks weren’t that lucky. More than a few actively traded companies fell every single trading day last week, and more often than not it happened without any material news. Investors just decided to move on, and the small daily downticks added up to double-digit percentage share-price declines.

Let’s take a closer look at five of the companies that saw their share prices drop in each of this past week’s five trading days.

Company

Mar. 22

Weekly Loss

JDS Uniphase

$13.47

(12%)

Nabors Industries

$15.41

(11%)

Ariad Pharmaceuticals

$19.38

(11%)

Dendreon

$4.89

(10%)

Amarin Pharmaceuticals

$7.63

(10%)

Source: Barron’s.

JDS Uniphase offered product updates during the Optical Fiber Communication Conference/National Fiber Optic Engineers Conference during the week. The optical networking specialist announced the availability of several new items. It wasn’t enough. Even though JDS Uniphase is still growing — analysts see marginal upticks in revenue and profitability for the fiscal year ending in June — investors were still set on rotating out of a company that had hit a fresh 52-week high last month.

Nabors Industries slipped despite an analyst upgrade. Zacks Equity Research is boosting its rating on Nabors from underperform to neutral, encouraged in part by the onshore contractor’s recent decision to start paying quarterly dividends. Then again, it’s not as if a hold rating is something to scrapbook.

Ariad Pharmaceuticals had good news on Friday, as the European equivalent of the FDA approved the company’s chronic myeloid leukemia (CML) drug Iclusig. One can argue that the market was already banking on approval, but is that any excuse for Ariad to close lower every single day last week?

Dendreon is another biotech that slumped on the week. The company kicked off the week by announcing that it had agreed to settle a securities class action lawsuit. It also presented at the 25th Annual ROTH Conference in California. These are typically events that push a stock higher. Settling complaints stemming from accusations that company executives made misleading statements a couple of years ago eliminates the uncertainty of the lawsuit’s financial obligations. Presenting at an analyst conference gives a company the opportunity to shine as it presents its bullish scenario. However, those events weren’t enough to keep sellers from moving on.

Finally, we have Amarin losing weight. The pharmaceutical stock got panned by Jim Cramer on Mad Money. “We’re going to veto it,” Cramer offered during Thursday’s Lightning Round segment. He compared it to the New York Mets without R.A. Dickey, the Cy Young winner that the team inexplicably …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Ariad's Potential Blockbuster Set for EU Debut

Leave a comment

By Max Macaluso, Ph.D., The Motley Fool

Filed under:

Biotech company Ariad Pharmaceuticals‘ quest to gain EU approval for its Chronic Myeloid Leukemia (CML) drug Iclusig is almost complete. Today, the company announced that the EU‘s CHMP recommended that the European Commission officially approve the drug. Why then, given this good news, did Ariad’s share price barely move following the announcement. Was the market largely expecting this approval? And looking longer term, who will Ariad have to compete with as it hopes to ramp up sales for its CML treatment? Health-care analyst Max Macaluso tackles these issues in the following video.

What macro trend was Warren Buffett referring to when he said, “This is the tapeworm that’s eating at American competitiveness?” Find out in our free report, What’s Really Eating at America’s Competitiveness. You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

The article Ariad’s Potential Blockbuster Set for EU Debut originally appeared on Fool.com.


Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';

var s = document.getElementsByTagName('script')[0];
s.parentNode.insertBefore(ga, s);
})();

Read | <a target=_blank href="http://www.dailyfinance.com/2013/03/22/ariads-potential-blockbuster-set-for-eu-debut/" rel="bookmark" title="Permanent …read more
Source: FULL ARTICLE at DailyFinance